- International figures, including Thomas Rachel and Penpa Tsering, are criticizing China's policies regarding Tibet, which are accused of leading to assimilation and control.
- Beijing extended legal reach to East Turkestan and entrenched assimilationist policies in Tibet while defending against Western criticism.
- Beijing's policies target ethnic minority regions, including laws that prioritize Mandarin over minority languages in Xinjiang and Tibet.
- Clinical trials involving major pharmaceutical companies are being conducted in Xinjiang, raising concerns about the risks posed by the region's policies.
Congressional investigation probes US firms Merck and Pfizer over clinical trials conducted in China and Xinjiang.
1 report, 1 independent
Updated Jul 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Congressional investigation probes US firms Merck and Pfizer over clinical trials conducted in China and Xinjiang.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Merck
public company in Indonesia
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
Related events
- Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.
- Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
- FDA and Pfizer are seeking regulatory approval for their products.
- Pfizer conducted initial clinical trials under government review.
- Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.